We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+6.39%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$779M
AUM Growth
-$45.9M
Cap. Flow
-$5.82M
Cap. Flow %
-0.75%
Top 10 Hldgs %
71.03%
Holding
35
New
6
Increased
2
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$46.6M
2
TVTX icon
Travere Therapeutics
TVTX
+$31.8M
3
NUVL
Nuvalent
NUVL
+$23.3M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$10.1M
5
ATYR
aTyr Pharma
ATYR
+$9.36M

Top Sells

Rank Stock Value
1
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$24.5M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$19.4M
3
EPIX
ESSA Pharma
EPIX
+$17.9M
4
RAPT
RAPT Therapeutics
RAPT
+$12.4M
5
KURA icon
Kura Oncology
KURA
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 96.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
1
Instil Bio
TIL
$48.3M
$123M 15.76%
343,254
– –
ACRS icon
2
Aclaris Therapeutics
ACRS
$726M
$82.2M 10.55%
4,563,962
– –
CLDX icon
3
Celldex Therapeutics
CLDX
$2.99B
$59.3M 7.62%
1,098,174
-142,436
-11% -$6.68M
WHWK
4
Whitehawk Therapeutics
WHWK
$190M
$44.9M 5.77%
+1,529,402
New +$46.6M
VTGN icon
5
VistaGen Therapeutics
VTGN
$9.89M
$44M 5.65%
534,910
– –
ALT icon
6
Altimmune
ALT
$552M
$43M 5.52%
3,800,000
+300,000
+9% +$3.65M
OLMA icon
7
Olema Pharmaceuticals
OLMA
$1B
$42.3M 5.44%
1,536,193
– –
TVTX icon
8
Travere Therapeutics
TVTX
$5.2B
$42M 5.4%
+1,732,410
New +$31.8M
RLMD icon
9
Relmada Therapeutics
RLMD
$557M
$36.4M 4.67%
1,387,720
– –
GHRS icon
10
GH Research
GHRS
$1.93B
$36.2M 4.65%
1,642,296
+366,465
+29% +$7.46M
KNTE
11
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$33.9M 4.36%
1,473,014
– –
MRNS
12
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$30.1M 3.86%
2,641,809
– –
LENZ
13
LENZ Therapeutics
LENZ
$166M
$26.4M 3.39%
230,374
– –
CNTA
14
DELISTED
Centessa Pharmaceuticals
CNTA
$18.8M 2.42%
1,127,272
– –
NUVL
15
DELISTED
Nuvalent
NUVL
$18.1M 2.33%
+803,951
New +$23.3M
CRVS icon
16
Corvus Pharmaceuticals
CRVS
$1.12B
$16.6M 2.13%
+3,427,461
New +$10.1M
CGEM icon
17
Cullinan Oncology
CGEM
$1.01B
$15.9M 2.05%
706,050
-270,095
-28% -$7.22M
ATYR
18
aTyr Pharma
ATYR
$47.6M
$14.2M 1.83%
+1,565,000
New +$9.36M
LONA
19
LeonaBio Inc
LONA
$66.3M
$11.2M 1.44%
119,620
-28,881
-19% -$2.94M
PHVS icon
20
Pharvaris
PHVS
$2.28B
$9.8M 1.26%
552,882
-350,000
-39% -$5.99M
COGT icon
21
Cogent Biosciences
COGT
$6.65B
$9.16M 1.18%
1,088,817
– –
CVRX icon
22
CVRx
CVRX
$137M
$8.82M 1.13%
533,370
-100,000
-16% -$1.92M
AKYA
23
DELISTED
Akoya BioSciences
AKYA
$5.58M 0.72%
400,000
– –
ATXS
24
DELISTED
Astria Therapeutics
ATXS
$4.76M 0.61%
538,999
-1
-0% -$10
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.81M 0.23%
+390,707
New +$1.62M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q3 2021 Portfolio in Review

As of Q3 2021, VR Adviser held 35 positions worth $779M, down 5.6% from $824M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

VR Adviser's Q3 2021 filing shows 6 new, 2 increased, 6 reduced and 9 closed positions. Its largest new stake was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M. The largest sale was Provention Bio, Inc. Common Stock, an estimated $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier.

  • VR Adviser's largest Q3 2021 buy was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M.
  • VR Adviser added most to GH Research in Q3 2021, an estimated $7.46M increase.
  • VR Adviser's biggest Q3 2021 reduction was Cullinan Oncology, cutting an estimated $7.22M.
  • VR Adviser fully exited Provention Bio, Inc. Common Stock in Q3 2021, selling an estimated $24.5M.
  • VR Adviser's ten largest holdings make up 71% of its $779M portfolio in Q3 2021.
  • VR Adviser opened 6 new positions and closed 9 in Q3 2021.
  • VR Adviser's portfolio value fell 5.6% quarter-over-quarter to $779M.

Based on VR Adviser's 13F filing for Q3 2021, filed 15 Nov 2021.